The Difference is in The PatchTM
The Difference is Oxytrol®


Letter to Pharmacist | Patient Counseling Information | Ordering OXYTROL


Letter to Pharmacist

the first and only transdermal system for overactive bladder

Dear Pharmacist:
Actavis Pharma, Inc., is proud to market OXYTROL, the first and only transdermal matrix system for the treatment of overactive bladder.

OXYTROL, a unique transdermal matrix system, delivers the proven efficacy of oxybutynin for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.[1,2] In clinical trials, patients treated with OXYTROL experienced up to a 75% reduction in incontinence episodes (placebo group experienced a 50% reduction in incontinence episodes).[1]

The transdermal delivery of OXYTROL provides a favorable safety profile. Anticholinergic adverse events, such as dry mouth, constipation , and dizziness were not significantly different than placebo in clinical. trials[1,3,*] No serious adverse events related to treatment were reported. The most common adverse events were application site reactions, primarily pruritis and erythema. Most treatment-related adverse events were described as mild or moderate in intensity.[1] Approximately 11% of patients discontinued treatment in clinical trials due to adverse events; most were secondary to application site reactions. No patients discontinued due to dry mouth.[1]

OXYTROL provides ALL-DAY and ALL-NIGHT delivery of oxybutynin for up to 4 days, allowing for convenient twice-weekly dosing.[1] Because of its transdermal delivery, OXYTROL bypasses first-pass gastric and hepatic metabolism and delivers more oxybutynin with 80% less N-desethyloxybutynin (N-DEO) metabolite at less than half the daily dose of oral immediate-release oxybutynin.[1]

OXYTROL is available as a 1-month supply of 8 patches contained in a patient calendar box. Each OXYTROL patch delivers 3.9 mg of oxybutynin per day. Patients should select any 2-day combination listed on the box as their schedule for changing the patch—and then stick with it. Thin, flexible, and virtually transparent, OXYTROL can be applied on the hip, abdomen, or buttock—absorption is bioequivalent.[1] Patients should be instructed to choose a new site with each application and avoid reapplication to the same site within 7 days.

Thank you for your continued support.

Gary Kozloski, PharmD
Vice President, Medical Affairs
Actavis Laboratories, Inc.

OXYTROL is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. OXYTROL is also contraindicated in patients who have demonstrated hypersensitivity to oxybutynin or other components of the product. OXYTROL should be administered with caution in the following patients: those with hepatic or renal impairment; clinically significant bladder outflow obstruction; gastrointestinal obstructive disorders because of the risk of gastric retention; patients with gastroesophageal reflux.

*Comparison significant if P<.05.
[1] OXYTROL Prescribing Information.
[2] Dmochowski RR, Davila GW, Zinner NR, et al, for the Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580-586.
[3] Data on file, Watson Pharma, Inc.

Ordering OXYTROL >>